Herceptin sBLA (correction)
Executive Summary
Roche/Genentech submitted a supplemental BLA for Herceptin for adjuvant treatment of early stage HER2-positive breast cancer in the first quarter and plan to file an sBLA for HER2-positive advanced gastric cancer in 2008; "The Pink Sheet" incorrectly reported that trastuzumabwas also under review for first-line, non-squamous non-small cell lung cancer (1"The Pink Sheet" June 26, 2006, p. 17). The firms' Avastin has an sBLA pending for that use...
You may also be interested in...
Roche To Build On Pharma, Diagnostics Expertise For Personalized Medicine
Roche sees its capabilities with both drug and diagnostics development as the key to maintaining a leadership position in targeted oncologics and personalized medicine
Switzerland: US FDA’s Medtech Can Bridge Innovation Gap Left By MDR
Setting the patient safety bar too high will likely have the opposite effect in the case of the EU MDR. So believes the medtech industry in Switzerland, where work has begun at government level to pave the way for Swiss patients to have access to US FDA-approved medtech.
Cordio Medical Is Using Patients’ Voices To Spot Heart Failure
As fluid builds up in the lungs, the “engine” of a patient’s voice is smothered. Medtech Insight spoke to Cordio Medical’s CEO about how the company’s smartphone-based software could warn clinicians almost three weeks in advance of decompensation.